CN1739546A - Use of skullcap aglycone and baicalin in preparing antitumor medicine - Google Patents
Use of skullcap aglycone and baicalin in preparing antitumor medicine Download PDFInfo
- Publication number
- CN1739546A CN1739546A CN 200510109720 CN200510109720A CN1739546A CN 1739546 A CN1739546 A CN 1739546A CN 200510109720 CN200510109720 CN 200510109720 CN 200510109720 A CN200510109720 A CN 200510109720A CN 1739546 A CN1739546 A CN 1739546A
- Authority
- CN
- China
- Prior art keywords
- baicaligenin
- baicalin
- group
- tumor
- matched group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 title claims abstract description 28
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 title claims abstract description 28
- 229960003321 baicalin Drugs 0.000 title claims abstract description 28
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 10
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 title abstract 3
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 title abstract 3
- 241000050051 Chelone glabra Species 0.000 title abstract 3
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 title abstract 3
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 30
- 206010028980 Neoplasm Diseases 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 12
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000037396 body weight Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 208000032839 leukemia Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 201000010174 renal carcinoma Diseases 0.000 description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- -1 flavone compounds Chemical class 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 201000011061 large intestine cancer Diseases 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- HRQGCQVOJVTVLU-UHFFFAOYSA-N bis(chloromethyl) ether Chemical compound ClCOCCl HRQGCQVOJVTVLU-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the new medicinal use of skullcap aglycone and baicalin, and is especially the use of skullcap aglycone and baicalin in preparing antitumor medicine.
Description
The present invention is innovation and creation " baicaligenin and derivant thereof, the analog purposes in the preparation the antitumor drug " (applyings date: on May 14th, 2004, application number: the dividing an application of application for a patent for invention 200410018368.7).
Technical field
The present invention relates to the pharmaceutical applications of a kind of baicaligenin and baicalin, be specifically related to baicaligenin and the baicalin purposes in the preparation antitumor drug.
Background technology
Baikal skullcap root (Scutellaria baicalensis Georgi) head is stated from Shennong's Herbal, has another name called Huang Wen, no a kind of reed mentioned in ancient books etc.Its pharmacological effect bitter in the mouth, cold in nature, function let out excess-fire, it is damp and hot to remove, and has effects such as antibacterial, heat extraction, detoxifcation, calmness, blood pressure lowering, function of gallbladder promoting.
Baicalin and baicaligenin are main flavone compounds contained in the Radix Scutellariae, and both have common flavone precursor structure:
Baicaligenin is one of main active of Radix Scutellariae.Molecular weight 270.25 can be got by the baicalin hydrolysis.Its chemical constitution is: 5,6,7 three hydrogen base-H are replaced by hydroxyl-OH on the flavone precursor structure.
The chemical constitution of baicalin is: 5,6 two hydrogen base-H are replaced by hydroxyl-OH on the flavone precursor structure, go up hydroxyl-OH and glucuronic acid condensation, i.e. baicaligenin-7-O-glucuronic acid for 7.
Bibliographical information is arranged in recent years, and baicalin and baicaligenin are to the growth of the breast cancer cell of In vitro culture inhibited (So F.V., et al.Cancer Lett., 112:127-133,1997).Also there are patent documentation report baicalin and baicaligenin that esophageal carcinoma and stomach cancer cell are had clearly lethal effect (Chinese patent application number 03109933.5; Chinese patent application number 03109942.4).
Do not see relevant baicalin and baicaligenin report so far to the active anticancer of other cancer strains.
Summary of the invention
Purpose of the present invention is intended to seek and develop the new medical usage of baicaligenin and baicalin, and a kind of baicaligenin and the baicalin purposes in the preparation antitumor drug is provided.
The inventor finds that after deliberation baicaligenin and baicalin can obviously suppress the activity of kinds of tumor cells, so can be used for preparing antitumor drug, wherein said tumor includes but not limited to: leukemia, pulmonary carcinoma, hepatocarcinoma, cervical cancer, renal carcinoma or colorectal cancer.
Above-claimed cpd all can extract from Radix Scutellariae or obtains by commercial sources by the conventional method of this area.
The officinal salt of chemical compound of the present invention comprises various inorganic or acylate example hydrochloric acid salt, hydrobromate, phosphate, sulfate, citrate, lactate, tartrate, maleate, fumarate, mandelate and oxalates; (TRIS is tromethane) with N-methyl-glucamine for various inorganic or organic alkali salts such as sodium hydroxide, Tris.
The prodrug of chemical compound of the present invention comprises that the carboxylate that contains this chemical compound (can be by the conventional method C of this area
1-4Pure and strong contraction get), the hydroxy ester that contains this chemical compound (can be by the conventional method C of this area
1-4Carboxylic acid, C
3-6Dicarboxylic acids or its anhydride, as maleic anhydride, fumaric acid anhydride etc. are concentrated to be made), the enamine that contains this chemical compound (can be by the conventional method C of this area
1-4Aldehydes or ketones concentrate make) or contain the acetal of this chemical compound or ketal (can concentrate with chloromethyl methyl ether or chloromethyl ether by the conventional method of this area and make) etc. (Albert S.Kearney Advanced Drug Reviews.19 (1996): 229-234)..
Baicaligenin of the present invention and baicalin can use separately or use with the form of pharmaceutical composition.Pharmaceutical composition comprise as the baicaligenin of active ingredient and or baicalin and pharmaceutically suitable carrier.
Described pharmaceutically suitable carrier is various excipient substances commonly used such as filler (Lactis Anhydrous, starch, lactose beadlet, glucose), binding agent (microcrystalline Cellulose), disintegrating agent (crosslinked carboxymethyl fecula sodium, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, cross-linked pvp), lubricant (magnesium stearate) and absorption enhancer, absorption carrier, flavouring agent, sweeting agent, diluent, excipient, wetting agent etc.
Described pharmaceutical composition can and can pass through intestinal or non-intestinal or topical routes by the preparation of this area conventional method.Oral formulations comprises tablet, granule, capsule, suspension, solution etc., and non-intestinal drug delivery agent comprises injection; Local administration preparation comprises as cream, ointment, patch, spray etc.
The route of administration of described medicine can be oral, Sublingual, subcutaneous, muscle, mucosa, urethra, vagina, vein etc.
The consumption of baicaligenin of the present invention and baicalin or its pharmaceutical composition can be according to route of administration, patient's age and body weight, the difference of the tumor type for the treatment of and the order of severity and difference, its daily dose can be 0.001～100mg/kg, can be in single or divided doses.
The specific embodiment
The invention will be further described below in conjunction with specific embodiment.But and do not mean that the present invention only limits to this.
Embodiment 1 baicalin and baicaligenin are tested the tumor cell in vitro Growth Inhibition
Be subjected to the reagent thing: baicalin and baicaligenin (existing goods) are dissolved in dimethyl sulfoxide (DMSO), use by 1/1000 dilution during actual the test.
The positive control medicine: 5-fluorouracil, be dissolved in DMSO, use by 1/1000 dilution during actual the test.
Method and result:
Determine baicalin and baicaligenin by the MTT algoscopy propagation of human lung carcinoma cell line A549, human leukemia cell line HL60, human cervical carcinoma cell strain Hela, human large intestine cancer cell strain HCT116, human hepatoma cell strain HepG2, human renal carcinoma cell strain RXF-631L is suppressed to measure each IC50 concentration, and the IC50 concentration of positive control medicine 5-fluorouracil.Simultaneously in contrast with people's normal fiber cell.
Assay method:
Above-mentioned each cell strain is suspended in the cell culture fluid that contains 10% (little) fetal bovine serum, with 2 * 10
4/ hole is seeded in 96 porocyte culture plates.After cultivating 24 hours, add baicalin or baicaligenin in culture fluid, ultimate density baicaligenin 0.3-200 μ g/ml, baicalin 0.6-350 μ g/ml, 5-fluorouracil 0.01-10 μ g/ml.Cultivate and make MTT mensuration after 3 days.With each cell of not adding baicalin and baicaligenin in contrast, test out each tumor cell 50% increased and stop concentration (IC50).
The results are shown in Table 1
Table 1
| Cell category | Baicalin IC50 concentration (μ M) | Baicaligenin IC50 concentration (μ M) | 5-fluorouracil IC50 concentration (μ M) |
| Human renal carcinoma cell strain RXF-631L | 35.1 | 19.2 | 2 |
| Human cervical carcinoma cell strain Hela | 55.2 | 18.5 | 8 |
| Human hepatoma cell strain HepG2 | 50.5 | 20.2 | 5 |
| Human lung carcinoma cell line A549 | 45.3 | 25.5 | 2 |
| Human leukemia cell line HL60 | 8 | 5 | 0.6 |
| Human large intestine cancer cell strain HCT116 | 28.7 | 15,7 | 2 |
| People's normal fiber cell | ＞1000 | ＞1000 | 10 |
The result shows that baicalin and baicaligenin are all had clearly inhibitory action to trying tumor cell.And compare with positive control medicine 5-fluorouracil, baicalin and baicaligenin do not have any toxic action to people's normal fiber cell.
Embodiment 2 baicaligenins suppress to be implanted in the growth of pulmonary carcinoma on the living animal
Experiment material: BALB/c nu/nu Mus, male, 6 weeks are big, and body weight is about 20 grams.
Be subjected to the reagent thing: baicaligenin (existing goods) is dissolved in glycofurol and uses.
Experimental technique and result:
Earlier under the BALB/c nu/nu Corium Mus that the human lung cancer cell A549 is inoculated in, and with animal be divided into matched group and height (20mg/kg), in (10mg/kg), low (5mg/kg) dosage group and positive drug group, 6 every group.To inject the animal abdominal cavity to be dissolved in glycofurol baicaligenin 0.1ml after inoculating for two weeks, injection in per four days once.Take out lump 5-7 day after being to inject for the third time and measure volume.Average external volume and administration group with matched group are compared.
The assay method of gross tumor volume; { minor axis
2* major diameter } * 0.5
Tumor minification={ 1-(average external volume of the average external volume/matched group of administration group) } * 100%
The results are shown in Table 2
Table 2
| Tumor minification % | |
| Matched group | 0 |
| Low dose group | 15 |
| Middle dosage group | 32 |
| High dose group | 62 |
Table 2 shows that baicaligenin has tangible inhibitory or killing effect to transplanting lung carcinoma cell, and is wherein obvious with high dose group.
Embodiment 3 baicaligenins suppress to be implanted in the growth of colorectal cancer on the living animal
Experiment material: BALB/c nu/nu Mus, male, 6 weeks are big, and body weight is about 20 grams.
Be subjected to the reagent thing: baicaligenin (existing goods) is dissolved in glycofurol.
Experimental technique and result:
Earlier under the BALB/c nu/nu Corium Mus that human large intestine cancer cell HCT116 is inoculated in, and with animal be divided into matched group and height (20mg/kg), in (10mg/kg), low (5mg/kg) dosage group, 6 every group.To inject the animal abdominal cavity to be dissolved in glycofurol baicaligenin 0.1ml after inoculating for two weeks, injection in per four days once.Take out lump 5-7 day after being to inject for the third time and measure volume.Average external volume and administration group with matched group are compared.
The assay method of gross tumor volume; { minor axis
2* major diameter } * 0.5
Tumor minification={ 1-(average external volume of the average external volume/matched group of administration group) } * 100%
The results are shown in Table 3
Table 3
| Tumor minification % | |
| Matched group | 0 |
| Low dosage is thin | 29 |
| Middle dosage group | 40 |
| High dose group | 68 |
Table 3 shows that baicaligenin has tangible inhibitory or killing effect to transplanting colorectal cancer cells, and is wherein obvious with high dose group.
Embodiment 4 baicaligenins suppress to be implanted in the growth of hepatocarcinoma on the living animal
Experiment material; BALB/c nu/nu Mus, male, 6 weeks are big, and body weight is about 20 grams.
Be subjected to the reagent thing; Baicaligenin (existing goods) is dissolved in glycofurol.
Experimental technique and result;
Earlier under the BALB/c nu/nu Corium Mus that human liver cancer cell HepG2 is inoculated in, and with animal be divided into matched group and height (20mg/kg), in (10mg/kg), low (5mg/kg) dosage group, 6 every group.To inject the animal abdominal cavity to be dissolved in glycofurol baicaligenin 0.1ml after inoculating for two weeks, injection in per four days once.Take out lump 5-7 day after being to inject for the third time and measure volume.Average external volume and administration group with matched group are compared.
The assay method of gross tumor volume; { minor axis
2* major diameter } * 0.5
Tumor minification={ 1-(average external volume of the average external volume/matched group of administration group) } * 100%
The results are shown in Table 4
Table 4
| Tumor minification % | |
| Matched group | 0 |
| Low dose group | 18 |
| Middle dosage group | 32 |
| High dose group | 65 |
Table 4 shows that baicaligenin has tangible inhibitory or killing effect to the liver transplantation cancerous cell, and is wherein obvious with high dose group.
Embodiment 5 baicaligenins suppress to be implanted in the growth of cervical cancer on the living animal
Experiment material: BALB/c nu/nu Mus, male, 6 weeks are big, and body weight is about 20 grams.
Be subjected to the reagent thing: baicaligenin (existing goods) is dissolved in glycofurol.
Experimental technique and result:
Earlier under the BALB/c nu/nu Corium Mus that human cervical carcinoma cell strain Hela is inoculated in, and with animal be divided into matched group and height (20mg/kg), in (10mg/kg), low (5mg/kg) dosage group, 6 every group.To inject the animal abdominal cavity to be dissolved in glycofurol baicaligenin 0.1ml after inoculating for two weeks, injection in per four days once.Take out lump 5-7 day after being to inject for the third time and measure volume.Average external volume and administration group with matched group are compared.
The assay method of gross tumor volume: { minor axis
2* major diameter } * 0.5
Tumor minification={ 1-(average external volume of the average external volume/matched group of administration group) } * 100%
The results are shown in Table 5
Table 5
| Tumor minification % | |
| Matched group | 0 |
| Low dose group | 20 |
| Middle dosage group | 35 |
| High dose group | 69 |
The shown baicaligenin of table 5 has tangible inhibitory or killing effect to the transplanted kidney cancerous cell, and is wherein obvious with high dose group.
Embodiment 6 baicaligenins suppress to be implanted in the growth of renal carcinoma on the living animal
Experiment material: BALB/c nu/nu Mus, male, 6 weeks are big, and body weight is about 20 grams.
Be subjected to the reagent thing: baicaligenin (existing goods) is dissolved in glycofurol.
Experimental technique and result:
Earlier under the BALB/c nu/nu Corium Mus that human renal carcinoma cell strain RXF-631L is inoculated in, and animal is divided into (10mg/kg) low (5mg/kg) dosage group in matched group and the height (20mg/kg), 6 every group.To inject the animal abdominal cavity to be dissolved in glycofurol baicaligenin 0.1ml after inoculating for two weeks, injection in per four days once.Take out lump 5-7 day after being to inject for the third time and measure volume.Average external volume and administration group with matched group are compared.
The assay method of gross tumor volume: { minor axis
2* major diameter } * 0.5
Tumor minification={ 1-(average external volume of the average external volume/matched group of administration group) } * 100%
The results are shown in Table 6
Table 6
| Tumor minification % | |
| Matched group | 0 |
| Low dose group | 19 |
| Middle dosage group | 36 |
| High dose group | 69 |
Table 6 shows that baicaligenin has tangible inhibitory or killing effect to the transplanted kidney cancerous cell, and is wherein obvious with high dose group.
Embodiment 7 baicaligenins suppress to be implanted in the growth of leukaemia on the living animal
Experiment material: BALB/c nu/nu Mus, male, 6 weeks are big, and body weight is about 20 grams.
Be subjected to the reagent thing: baicaligenin (existing goods) is dissolved in glycofurol.
Experimental technique and result:
Earlier with leukaemia HL60 1 * 10
8Be inoculated in the intraperitoneal of BALB/c nu/nu Mus, inoculate after 48 hours, with animal be divided into matched group and height (20mg/kg), in (10mg/kg), low (5mg/kg) dosage group, 6 every group.To be dissolved in glycofurol baicaligenin 0.1ml and inject the animal intraperitoneal.Injection in per four days is once injected three times altogether.The average survival time number of days and administration group with matched group are compared.
Life-delaying rate (ILS)=(the The average survival time number of days of the The average survival time number of days/matched group of administration group) * 100%
The results are shown in Table 7
Table 7
| ILS％ | |
| Matched group | |
| Low dose group | 120 |
| Middle dosage group | 150 |
| High dose group | 180 |
Table 7 shows that baicaligenin has the prolongation effect to the existence of transplanting the leukaemia Mus, and its result shows that baicaligenin has tangible leukemia resisting action.
Claims (2)
1. baicalin is in the purposes of preparation in the medicament for resisting cervical cancer.
2. baicaligenin is in the purposes of preparation in the medicament for resisting cervical cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510109720 CN1739546A (en) | 2004-05-14 | 2004-05-14 | Use of skullcap aglycone and baicalin in preparing antitumor medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510109720 CN1739546A (en) | 2004-05-14 | 2004-05-14 | Use of skullcap aglycone and baicalin in preparing antitumor medicine |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410018368 Division CN1267093C (en) | 2004-05-14 | 2004-05-14 | Usage of baicalin and its derivatives, analogs in the preparation process of tumor resisting medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1739546A true CN1739546A (en) | 2006-03-01 |
Family
ID=36092170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510109720 Pending CN1739546A (en) | 2004-05-14 | 2004-05-14 | Use of skullcap aglycone and baicalin in preparing antitumor medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1739546A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021175333A1 (en) * | 2020-03-06 | 2021-09-10 | 南京施江医药科技有限公司 | Scutellariae radix compounds and use thereof for inhibiting oxidative phosphorylation pathway of mitochondria |
-
2004
- 2004-05-14 CN CN 200510109720 patent/CN1739546A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021175333A1 (en) * | 2020-03-06 | 2021-09-10 | 南京施江医药科技有限公司 | Scutellariae radix compounds and use thereof for inhibiting oxidative phosphorylation pathway of mitochondria |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516478A (en) | Compositions and methods for immunotherapy | |
| CN1951369A (en) | Coated nanoliposomes of resveratrol and preparation method thereof | |
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| CN101612400A (en) | 1 application of receptor antagonist in antitumor of angiotensin | |
| TWI547277B (en) | Honokiol for the treatment or prevention of bladder cancer growth and metastasis and improve the cachexia new use | |
| CN114522158B (en) | Metabolite for preparing medicament for treating liver cancer and application thereof | |
| CN1943675A (en) | Tibetan medicinal composition for expectorant, antitussive, antiasthmatic and its preparation method | |
| CN1267093C (en) | Usage of baicalin and its derivatives, analogs in the preparation process of tumor resisting medicine | |
| CN1785384A (en) | Chinese medicinal composition for treating tuberculosis and its preparation method | |
| CN105726631A (en) | Application of officinal magnolia bark extract to prepare medicine for treating cow mastitis | |
| CN106748939A (en) | The new bromine phenol thiosemicarbazide compound of one class and its preparation and medicine and purposes | |
| CN101474173B (en) | Application of cumarin coumpound Murraya jasminorage ketone in preparing anti-tumor medicament | |
| CN1739546A (en) | Use of skullcap aglycone and baicalin in preparing antitumor medicine | |
| CN1718566A (en) | Ferulaic acid and its sodium salt used for preventing and treating senile dementia medicine | |
| CN1839855A (en) | Ginsenoside F1 medicinal uses | |
| CN107737103B (en) | A kind of intratumor injection liquid for treating rhabdomyosarcoma | |
| CN1053376C (en) | Antineoplastic Chinese medicine prepn and its prepn process | |
| CN1836684A (en) | Silktree albizzia general saponin and its extraction method, pharmaceutical use of the said composition and medicine preparation | |
| CN101658513A (en) | Use of isoliquiritigenin as medicament for preventing and treating or curing postoperative metastasis and relapse of malignant tumors | |
| CN1244332C (en) | Sarcandra extract and its application | |
| CN1872049A (en) | Combination of erigeron breviscapus and medication of chemotherapy in platinum class | |
| CN1276751C (en) | Application of scutellaria root extract in preparation of anti-stomach cancer medicine | |
| CN100446761C (en) | Application of scutellaria root extract in preparation of anti esophageal cancer medicine | |
| CN109846876B (en) | Application of lignan compound in resisting tumor and preparation of medicine thereof | |
| CN104173354B (en) | Can treating cancer pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI GELU AOLI BIO-MEDICAL TECHNOLOGY CO., LT Free format text: FORMER OWNER: WU YIXIN Effective date: 20060630 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20060630 Address after: Shanghai city GuoShouJing Road No. 351 Building No. 2 room 670-19 Applicant after: Shanghai Geluoli Biology Medicine Technology Co., Ltd. Address before: 200051 room 2, No. 700, Lane 1802, Changning District, Shanghai, Wuyi Road Applicant before: Wu Yixin |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |